Inflammatix snags $32 mln Series C
Burlingame, California-based Inflammatix, a molecular diagnostics company, has secured $32 million in Series C financing.
Burlingame, California-based Inflammatix, a molecular diagnostics company, has secured $32 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
